Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 4/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29424855 | 1.00 | NNMT (0.54) | NNMTBAZ2BHCAR3GRM5HDAC6 | |
| SCHEMBL217496 | 0.85 | NNMT (0.49) | NNMTHCAR3HDAC6HDAC1CA2 | |
| SCHEMBL18715411 | 0.85 | HCAR3 (0.70) | NNMTBAZ2BHCAR3GRM5HDAC6 | |
| SCHEMBL28117859 | 0.82 | NNMT (0.46) | NNMTHCAR3HDAC6HDAC1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28249483 | 0.81 | HCAR3 (0.65) | HCAR3 | |
| SCHEMBL11005841 | 0.81 | NNMT (0.53) | NNMTHCAR3 | |
| SCHEMBL22403855 | 0.81 | NNMT (0.46) | NNMTHCAR3HDAC6HDAC1 | |
| SCHEMBL12388325 | 0.81 | HCAR3 (0.51) | NNMTHCAR3 | |
| SCHEMBL19736133 | 0.81 | PTK2 (0.57) | NNMTBAZ2BHCAR3GRM5TSHR | |
| SCHEMBL8722229 | 0.79 | NNMT (0.50) | NNMTHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | UNIV MUENCHEN TECH (DE) | 2026-01-22 | — | — | US | claimed |
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) GMBH (NL) | 2025-09-23 | — | — | US | claimed |
| US-12390540-B2 | Dual mode radiotracer and -therapeutics | Technische Universität München (DE) | 2025-08-19 | — | — | US | claimed |
| EP-4291250-B1 | DUAL MODE RADIOTRACER AND THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2025-01-15 | — | — | EP | claimed |
| US-20240399001-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | Blue Earth Diagnostics Limited (GB) | 2024-12-05 | — | — | US | claimed |
| US-20240366811-A1 | RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOF | TIANJIN CONJUSTAR BIOLOGICS CO., LTD. (CN) | 2024-11-07 | — | — | US | claimed |
| WO-2024222840-A1 | NOVEL RADIONUCLIDE-LABELED POLYPEPTIDE CONJUGATE AND USE THEREOF | 天津星联肽生物科技有限公司 | 2024-10-31 | — | — | WO | claimed |
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-09-26 | — | — | US | claimed |
| EP-4424378-A2 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2024-09-04 | — | — | EP | claimed |
| US-20220370649-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | UNIV MUENCHEN TECH (DE) | 2022-11-24 | — | — | US | claimed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | claimed |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | Technische Universität München (DE) | 2022-04-21 | — | — | US | claimed |
| WO-2022018264-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2022-01-27 | — | — | WO | claimed |
| EP-3917582-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | Technische Universität München (DE) | 2021-12-08 | — | — | EP | claimed |
| CN-113573743-A | Diagnostic imaging agents for cancer | 慕尼黑工业大学 | 2021-10-29 | — | — | CN | claimed |
| WO-2020157184-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | Technische Universität München (DE) | 2020-08-06 | — | — | WO | claimed |
| US-20200197545-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | TECHNISCHE UNIVERSITÄT MÜNCHEN - KLINIKUM RECHTS DER ISAR (DE) | 2020-06-25 | — | — | US | claimed |
| EP-3658194-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2020-06-03 | — | — | EP | claimed |
| WO-2019020831-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2019-01-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370649-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | PAICS, SSTR2, SSTR1 | NNMT 1537/4885BAZ2B 2545/4885HCAR3 1300/4885 |
| US-12419976-B2 | Hybrid tracers for targeted cancer imaging and treatment | HNRNPF, ANXA3, SLC67A1 | NNMT 4701/4885BAZ2B 2574/4885HCAR3 2637/4885 |
| US-20240366811-A1 | RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOF | GRPR, SSTR4, DNPEP | NNMT 3985/4885BAZ2B 2603/4885HCAR3 2013/4885 |
| US-20260021211-A1 | Dual mode radiotracer and -therapeutics | FOLH1, SLC19A1, KLK3 | NNMT 3874/4885BAZ2B 1269/4885HCAR3 1637/4885 |
| US-20240399001-A1 | RADIOTRACERS AND THERAPEUTICS BINDING TO FIBROBLAST ACTIVATION PROTEIN (FAP) | FAP, FIBP, FGFR1 | NNMT 4197/4885BAZ2B 2804/4885HCAR3 1746/4885 |
| US-20200197545-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | SSTR2, SSTR1, PAICS | NNMT 1583/4885BAZ2B 2240/4885HCAR3 1208/4885 |
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | SSTR1, SSTR3, SSTR4 | NNMT 3359/4885BAZ2B 2392/4885HCAR3 145/4885 |
| US-12390540-B2 | Dual mode radiotracer and -therapeutics | PAICS, SSTR2, SSTR1 | NNMT 1537/4885BAZ2B 2545/4885HCAR3 1300/4885 |
| US-20220118120-A1 | CANCER DIAGNOSTIC IMAGING AGENTS | FOLH1, FOLR1, KLK3 | NNMT 3845/4885BAZ2B 2786/4885HCAR3 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.